- ►annals.org [PDF] SL Greenspan, JB Nelson, DL Trump, NM … - Annals of internal medicine, 2007 - Am Coll Physicians Page 1. Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen
Deprivation Therapy for Prostate Cancer A Randomized Trial ... Cited by 50 - Related articles - BL Direct - All 5 versions
- ►jcojournal.org MD Michaelson, DS Kaufman, H Lee, FJ … - Journal of Clinical Oncology, 2007 - jcojournal.org Results Mean (± SE) BMD of the posteroanterior lumbar spine decreased by 3.1%
± 1.0% in men assigned to placebo and increased by 4.0% ± 1.0% in men assigned
to zoledronic acid (P < .001). BMD of the total hip decreased by 1.9% ± ... Cited by 57 - Related articles - All 8 versions
MR Smith, SP Boyce, E Moyneur, MS Duh, MK … - The Journal of urology, 2006 - Elsevier Using a database of medical claims from 16 large American companies we
identified a study group of 3,779 men with prostate cancer who received
treatment with a GnRH agonist and a control group of 8,341 with prostate ... Cited by 66 - Related articles - BL Direct - All 10 versions
- ►ascopubs.org MR Smith, WC Lee, J Brandman, Q Wang, M … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org RESULTS: In men with nonmetastatic prostate cancer, GnRH agonists significantly
increased fracture risk. The rate of any clinical fracture was 7.88 per 100
person-years at risk in men receiving a GnRH agonist compared with 6.51 per ... Cited by 81 - Related articles - All 8 versions
- ►syntaxxcomm.com [PDF] RS Israeli, SJ Rosenberg, DR Saltzstein, JE … - Clinical Genitourinary Cancer, 2007 - CIG Media Group Key words: Bisphosphonates, Bone loss, Osteoporosis, Prostate cancer ...
Submitted: Jun 30, 2006; Revised: Jul 28, 2006; Accepted: Aug 15, 2006 ...
Address for correspondence: Ron S. Israeli, MD Staten Island Urological ... Cited by 21 - Related articles - BL Direct - All 3 versions
CW Ryan, D Huo, LM Demers, TM Beer, LV … - The Journal of urology, 2006 - Elsevier Patients with prostate cancer without bone metastases who had received androgen
deprivation therapy for 12 months or less were randomized to 4 mg zoledronic
acid or placebo intravenously every 3 months for 1 year. Patients were ... Cited by 27 - Related articles - All 6 versions
- ►endojournals.org SL Greenspan, P Coates, SM Sereika, JB … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Context: Although androgen deprivation therapy (ADT) for prostate cancer is
associated with bone loss, little is known about when this bone loss occurs. ... Objective: We postulated that men on ADT would experience the greatest ... Cited by 71 - Related articles - BL Direct - All 7 versions
J Morote, JP Morin, A Orsola, JM Abascal, C … - Urology, 2007 - Elsevier Dual energy x-ray absorptiometry was used to assess the bone mineral density
(BMD) at the lumbar spine, femoral neck, Ward's triangle, trochanter, and total
hip in 390 patients free of bone metastases. Osteoporosis was diagnosed if ... Cited by 28 - Related articles - All 20 versions
- ►endojournals.org MR Smith, MA Fallon, H Lee, JS Finkelstein - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc GnRH agonists decrease bone mineral density and increase fracture risk in men
with prostate cancer. Raloxifene increases bone mineral density in
postmenopausal women, but its efficacy in hypogonadal men is not known. In ... Cited by 85 - Related articles - BL Direct - All 5 versions
- ►ascopubs.org SL Greenspan, JB Nelson, DL Trump, JM … - Journal of Clinical Oncology, 2008 - jco.ascopubs.org Results Men initially randomly assigned to alendronate and randomly reassigned
at year 2 to continue had additional bone density gains at the spine (mean, 2.3%
± 0.7) and hip (mean, 1.3% ± 0.5%; both P < .01); those randomly assigned ... Cited by 8 - Related articles - All 5 versions
